Yarrow Bioscience (YARW) Preferred Stock Liabilities (2016 - 2017)
Yarrow Bioscience's (YARW) quarterly Preferred Stock Liabilities came in at $44.8 million in Q4 2017, up 216.01% YoY from $14.2 million in Q4 2016, and up 216.01% on a QoQ basis from $14.2 million in Q4 2016.
Yarrow Bioscience (YARW) Preferred Stock Liabilities (2016 - 2017) Analysis & Trends
Yarrow Bioscience (YARW) has 2 years of Preferred Stock Liabilities data on file, last reported at $44.8 million in Q4 2017.
- Quarterly Preferred Stock Liabilities rose 216.01% year-over-year to $44.8 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $44.8 million (up 216.01% YoY) and the FY2017 annual result came in at $44.8 million, up 216.01% from the prior year.
- Preferred Stock Liabilities advanced to $44.8 million in Q4 2017, from $14.2 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $44.8 million in Q4 2017 to a low of $14.2 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 44.82 Mn |
| Dec 31, 2016 | 14.18 Mn |